Ursocholic acid是胆酸的7β-羟基差向异构体，具有高亲水性。
Cas No.:2955-27-3
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
Ursocholic acid is the 7β-hydroxy epimer of cholic acid, with highly hydrophilic[1]. Ursocholic acid can be well absorbed and excreted into the bile in animals, which is converted to deoxycholic acid by intestinal flora[2]. Ursocholic acid has been widely used in comparative studies on the regulation of bile acid secretion and gallstone dissolution[3].
In vivo, Ursocholic acid treatment via feeding at a dose of 5.4g/day for 5 weeks reduced the increase in gallbladder cholesterol and phospholipid levels in mice induced by the lithogenic diet, resulting in increased fecal excretion of deoxycholic acid and cholic acid[4].
References:
[1] Tonin F, Arends I W C E. Latest development in the synthesis of ursodeoxycholic acid (UDCA): a critical review[J]. Beilstein journal of organic chemistry, 2018, 14(1): 470-483.
[2] Tint S G, Batta A K, Dayal B, et al. Metabolism of ursocholic acid in humans: conversion of ursocholic acid to deoxycholic acid[J]. Hepatology, 1992, 15(4): 645-650.
[3] Howard P J, Gleeson D, Murphy G M, et al. Ursocholic acid: bile acid and bile lipid dose response and clinical studies in patients with gall stones[J]. Gut, 1989, 30(1): 97-103.
[4] Uchida K, Aklyoshi T, Igimi H, et al. Differential effects of ursodeoxycholic acid and ursocholic acid on the formation of biliary cholesterol crystals in mice[J]. Lipids, 1991, 26(7): 526-530.
Ursocholic acid是胆酸的7β-羟基差向异构体，具有高亲水性[1]。Ursocholic acid在动物体内可被有效吸收并排泄至胆汁中，经肠道菌群转化为脱氧胆酸[2]。Ursocholic acid已广泛应用于胆汁酸分泌调控与胆结石溶解的比较研究[3]。
在体内，以5.4g/day剂量的Ursocholic acid喂养5周，可抑制致结石饮食诱导的小鼠胆囊胆固醇和磷脂水平升高，同时促进粪便中脱氧胆酸和胆酸的排泄[4]。
| Animal experiment [1]: | |
Animal models | ICR strain male mice |
Preparation Method | ICR strain male mice, six-weeks-old, were kept in an air-conditioned room (25±1℃; 50-60% humidity) lighted 12 hours a day (8:00 a.m. to 8:00 p.m.). An ordinary powder diet was provided as a basal diet. The lithogenic diet was prepared by adding 0.5% cholesterol and 0.25% sodium cholate to the basal diet. The composition of the basal diet was as follows: 25.5% protein, 4.0% lipids, 53.5% carbohydrate, 4.0% fiber, 7.0% ash, and 6.0% water. The content of cholesterol was about 0.1%. The mice were given ad libitum tap water and lithogenic diet with Ursocholic acid (5.4g/day) for five weeks. Collect mouse samples for analysis. |
Dosage form | 5.4g/day for 5 weeks; p.o. |
Applications | Ursocholic acid treatment significantly reduced biliary bile acid level in mice and increased fecal excretion of deoxycholic acid and cholic acid. |
References: | |
| Cas No. | 2955-27-3 | SDF | |
| 别名 | 熊果胆酸 | ||
| Canonical SMILES | C[C@H](CCC(O)=O)[C@H]1CC[C@@]2([H])[C@]3([H])[C@@H](O)C[C@]4([H])C[C@H](O)CC[C@]4(C)[C@@]3([H])C[C@H](O)[C@]12C | ||
| 分子式 | C24H40O5 | 分子量 | 408.57 |
| 溶解度 | DMSO : 100 mg/mL (244.76 mM; Need ultrasonic); H2O : < 0.1 mg/mL (insoluble) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4476 mL | 12.2378 mL | 24.4756 mL |
| 5 mM | 489.5 μL | 2.4476 mL | 4.8951 mL |
| 10 mM | 244.8 μL | 1.2238 mL | 2.4476 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet